ADHESION DATA

Purposefully designed—and proven—to stay in place

Not actual size.

IN THE SECURE TRIAL

95%

OF THE 55,900 TWIRLA® PATCHES

adhered

Subject-reported adhesion was generally better for the abdomen as compared to the upper torso and buttock.

Full detachment rates were higher for transdermal systems exposed to water as compared to transdermal systems with no water exposure. Five percent of patches fully detached.

Advise women to check the patch for partial or complete detachment not only daily, but also after frequent and prolonged water exposure (30 minutes or more).

A total of 6.2% of women had application-related adverse reactions in the Twirla phase 3 trial (N=2031).*

In an investigator-assessed, phase 1 clinical study, 99% (77 of 78) of Twirla patches on the lower abdomen exhibited 75% or greater surface area adhesion for the full 7 days at all timepoints evaluated (every 24 hours).1

See Twirla’s demonstrated safety profile. SAFETY

*The SECURE Trial: an open-label, single-arm, multicenter trial in the US of 1-year duration that enrolled women ranging in age from 18 to 60 years.

A randomized, open-label, single-dose, 2-treatment, 2-period crossover non-inferiority study compared the 7-day adhesion of Twirla with the only other currently available contraceptive patch. The primary analysis included data from 78 women.1

IMPORTANT SAFETY INFORMATION

+

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS and CONTRAINDICATED IN WOMEN WITH A BMI ≥30 kg/m2

Cigarette Smoking and Serious Cardiovascular Events
Cigarette smoking increases the risk of serious cardiovascular events from combined hormonal contraceptive (CHC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, CHCs, including TWIRLA, are contraindicated in women who are over 35 years of age and smoke.
Contraindicated in Women with a BMI ≥30 kg/m2
TWIRLA is contraindicated in women with a BMI ≥30 kg/m2. Compared to women with a lower BMI, women with a BMI ≥30 kg/m2 had reduced effectiveness and may have a higher risk for venous thromboembolic events (VTEs).